These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 34458977)
1. Treatment of immune thrombocytopenia with eltrombopag in patients who had and who had not received prior rituximab: post-hoc analysis of the EXTEND study. Meyer O; Wong RSM; Khelif A; Stankovic M; Maier J; Saleh MN; Bussel JB Br J Haematol; 2022 Jan; 196(2):448-452. PubMed ID: 34458977 [No Abstract] [Full Text] [Related]
6. Two new drugs for chronic ITP. Med Lett Drugs Ther; 2009 Feb; 51(1305):10-1. PubMed ID: 19197233 [TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study. Grainger JD; Blanchette VS; Grotzinger KM; Roy A; Bussel JB Br J Haematol; 2019 Apr; 185(1):102-106. PubMed ID: 30592022 [TBL] [Abstract][Full Text] [Related]
8. Switching from eltrombopag to hetrombopag in patients with primary immune thrombocytopenia: a post-hoc analysis of a multicenter, randomized phase III trial. Mei H; Liu X; Li Y; Zhou H; Feng Y; Gao G; Cheng P; Huang R; Yang L; Hu J; Hou M; Yao Y; Liu L; Wang Y; Wu D; Shen X; Jin J; Luo J; Zeng Y; Zhou X; Xia R; Jiang Z; Bai Y; Niu T; Yang R; Hu Y Ann Hematol; 2024 Jul; 103(7):2273-2281. PubMed ID: 38842566 [TBL] [Abstract][Full Text] [Related]
9. Use of eltrombopag for secondary immune thrombocytopenia in clinical practice. González-López TJ; Alvarez-Román MT; Pascual C; Sánchez-González B; Fernández-Fuentes F; Pérez-Rus G; Hernández-Rivas JA; Bernat S; Bastida JM; Martínez-Badas MP; Martínez-Robles V; Soto I; Olivera P; Bolaños E; Alonso R; Entrena L; Gómez-Nuñez M; Alonso A; Yera Cobo M; Caparrós I; Tenorio M; Arrieta-Cerdán E; Lopez-Ansoar E; García-Frade J; González-Porras JR Br J Haematol; 2017 Sep; 178(6):959-970. PubMed ID: 28573819 [TBL] [Abstract][Full Text] [Related]
10. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Khellaf M; Viallard JF; Hamidou M; Cheze S; Roudot-Thoraval F; Lefrere F; Fain O; Audia S; Abgrall JF; Michot JM; Dauriac C; Lefort S; Gyan E; Niault M; Durand JM; Languille L; Boutboul D; Bierling P; Michel M; Godeau B Haematologica; 2013 Jun; 98(6):881-7. PubMed ID: 23445876 [TBL] [Abstract][Full Text] [Related]
11. Management of primary immune thrombocytopenia in a real-world setting in Japan: eltrombopag versus corticosteroids. Wong TF; Majewska R; Tomiyama Y Int J Hematol; 2021 Aug; 114(2):152-163. PubMed ID: 33851348 [TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis. Kolanis S; Vasileiou E; Hatzipantelis E; Economou M; Tragiannidis A Cardiovasc Hematol Agents Med Chem; 2021; 19(1):83-92. PubMed ID: 32914722 [TBL] [Abstract][Full Text] [Related]
13. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States. Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608 [TBL] [Abstract][Full Text] [Related]
14. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. Bussel JB; Cheng G; Saleh MN; Psaila B; Kovaleva L; Meddeb B; Kloczko J; Hassani H; Mayer B; Stone NL; Arning M; Provan D; Jenkins JM N Engl J Med; 2007 Nov; 357(22):2237-47. PubMed ID: 18046028 [TBL] [Abstract][Full Text] [Related]
15. Successful discontinuation of eltrombopag in one child with refractory primary immune thrombocytopenia and literature review. Wang X; Liu X; Wang L; Wang JY; Li A Blood Coagul Fibrinolysis; 2019 Mar; 30(2):71-74. PubMed ID: 30720490 [TBL] [Abstract][Full Text] [Related]
16. Eltrombopag--a novel approach for the treatment of chronic immune thrombocytopenic purpura: review and safety considerations. Cook L; Cooper N Drug Des Devel Ther; 2010 Jul; 4():139-45. PubMed ID: 20689640 [TBL] [Abstract][Full Text] [Related]
17. Eltrombopag in Immune Thrombocytopenia, Aplastic Anemia, and Myelodysplastic Syndrome: From Megakaryopoiesis to Immunomodulation. Fattizzo B; Levati G; Cassin R; Barcellini W Drugs; 2019 Aug; 79(12):1305-1319. PubMed ID: 31292909 [TBL] [Abstract][Full Text] [Related]
18. Molecule of the month. Eltrombopag. Drug News Perspect; 2008; 21(6):344. PubMed ID: 18836592 [No Abstract] [Full Text] [Related]
19. Thrombopoietin-receptor agonist as a treatment of thrombocytopenia associated with systemic lupus erythematosus. Moreno Martínez MJ; Gallego P; Moreno Ramos MJ Reumatol Clin; 2016; 12(1):57. PubMed ID: 26024588 [No Abstract] [Full Text] [Related]
20. Relative potency of the thrombopoietin receptor agonists eltrombopag, avatrombopag and romiplostim in a patient with chronic immune thrombocytopenia. Al-Samkari H; Kuter DJ Br J Haematol; 2018 Oct; 183(2):168. PubMed ID: 29978577 [No Abstract] [Full Text] [Related] [Next] [New Search]